Page 8 - Poster Section News Today

/PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, will...

/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...

Unique Structure and Tetravalency of FS118 Is Required to Modulate LAG-3 Cell Surface ExpressionCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 08, 2022(NASDAQ: FSTX), a clinical-stage biopharmaceutical

Investegate announcements from Ultimovacs ASA, Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development

/PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry- leading provider of drug discovery services, today announced that twelve abstracts...

/PRNewswire/ -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and...

TET platform shows efficient T cell priming and beneficial safety profile Data supported clinical transition to ongoing TENDU Phase I trialTET platform offers potential to strengthen T cell response to

/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...

PRINCETON, NJ / ACCESSWIRE / April 8, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from preclinical

NVL-520 showed strong preclinical activity against diverse ROS1 fusion partners and kinase-domain resistance mutations, as well as in a ROS1-driven model of...